Bioidentical Hormone Use High Among Women
The use of non-FDA-approved, bioidentical hormone therapy is increasing dramatically among menopausal women.
The use of non-FDA-approved, bioidentical hormone therapy is increasing dramatically among menopausal women.
The North American Menopause Society has launched a free mobile app to help clinicians and patients personalize treatment decisions.
The FDA has approved a new indication with a new dose of Minivelle (estradiol transdermal system) for prevention of postmenopausal osteoporosis.
Women with higher vitamin D levels during midlife may have a lower risk for fractures.
BMI and postmenopausal status are independently associated with breast white adipose tissue inflammation, according to research presented at 2014 ASCO Breast Cancer Symposium.
After menopause, women may continue to experience hot flashes for at least 5 years.
The Menopause Map facilitates discussion between patients and providers on the “menopause journey.”
Menopausal women seek treatment from anti-aging clinics because of concerns about traditional hormone therapy.
Limiting caffeine may aid with hot flashes and night sweats.
Hormone therapy does not affect progression of atherosclerosis.